vs
Cooper Companies (The)（COO）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
Cooper Companies (The)的季度营收约是莫德纳的1.0倍（$1.1B vs $1.0B），Cooper Companies (The)净利率更高（7.9% vs -19.7%，领先27.6%），Cooper Companies (The)同比增速更快（4.6% vs -45.4%），Cooper Companies (The)自由现金流更多（$149.9M vs $-880.0M），过去两年Cooper Companies (The)的营收复合增速更高（6.9% vs -45.0%）
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
COO vs MRNA — 直观对比
营收规模更大
COO
是对方的1.0倍
$1.0B
营收增速更快
COO
高出50.0%
-45.4%
净利率更高
COO
高出27.6%
-19.7%
自由现金流更多
COO
多$1.0B
$-880.0M
两年增速更快
COO
近两年复合增速
-45.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.0B |
| 净利润 | $84.6M | $-200.0M |
| 毛利率 | 61.1% | 79.6% |
| 营业利润率 | 13.2% | -25.6% |
| 净利率 | 7.9% | -19.7% |
| 营收同比 | 4.6% | -45.4% |
| 净利润同比 | -28.0% | -1638.5% |
| 每股收益（稀释后） | $0.42 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收COOMRNA
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $1.0B | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $964.7M | — | ||
| Q4 24 | $1.0B | $966.0M | ||
| Q3 24 | $1.0B | $1.9B | ||
| Q2 24 | $942.6M | — | ||
| Q1 24 | $931.6M | — |
净利润COOMRNA
| Q4 25 | $84.6M | — | ||
| Q3 25 | $98.3M | $-200.0M | ||
| Q2 25 | $87.7M | — | ||
| Q1 25 | $104.3M | — | ||
| Q4 24 | $117.5M | $-1.1B | ||
| Q3 24 | $104.7M | $13.0M | ||
| Q2 24 | $88.9M | — | ||
| Q1 24 | $81.2M | — |
毛利率COOMRNA
| Q4 25 | 61.1% | — | ||
| Q3 25 | 65.3% | 79.6% | ||
| Q2 25 | 67.8% | — | ||
| Q1 25 | 68.4% | — | ||
| Q4 24 | 66.5% | 23.5% | ||
| Q3 24 | 66.1% | 72.4% | ||
| Q2 24 | 67.0% | — | ||
| Q1 24 | 67.0% | — |
营业利润率COOMRNA
| Q4 25 | 13.2% | — | ||
| Q3 25 | 16.6% | -25.6% | ||
| Q2 25 | 18.4% | — | ||
| Q1 25 | 18.9% | — | ||
| Q4 24 | 19.5% | -129.0% | ||
| Q3 24 | 19.2% | -3.8% | ||
| Q2 24 | 17.2% | — | ||
| Q1 24 | 16.4% | — |
净利率COOMRNA
| Q4 25 | 7.9% | — | ||
| Q3 25 | 9.3% | -19.7% | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 10.8% | — | ||
| Q4 24 | 11.5% | -115.9% | ||
| Q3 24 | 10.4% | 0.7% | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 8.7% | — |
每股收益（稀释后）COOMRNA
| Q4 25 | $0.42 | — | ||
| Q3 25 | $0.49 | $-0.51 | ||
| Q2 25 | $0.44 | — | ||
| Q1 25 | $0.52 | — | ||
| Q4 24 | $0.59 | $-2.91 | ||
| Q3 24 | $0.52 | $0.03 | ||
| Q2 24 | $0.44 | — | ||
| Q1 24 | $0.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.6M | $1.1B |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $8.2B | $9.3B |
| 总资产 | $12.4B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.30× | — |
8季度趋势，按日历期对齐
现金及短期投资COOMRNA
| Q4 25 | $110.6M | — | ||
| Q3 25 | $124.9M | $1.1B | ||
| Q2 25 | $116.2M | — | ||
| Q1 25 | $100.9M | — | ||
| Q4 24 | $107.6M | $1.9B | ||
| Q3 24 | $109.7M | $1.6B | ||
| Q2 24 | $112.4M | — | ||
| Q1 24 | $135.2M | — |
总债务COOMRNA
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
股东权益COOMRNA
| Q4 25 | $8.2B | — | ||
| Q3 25 | $8.4B | $9.3B | ||
| Q2 25 | $8.3B | — | ||
| Q1 25 | $8.1B | — | ||
| Q4 24 | $8.1B | $10.9B | ||
| Q3 24 | $7.9B | $11.9B | ||
| Q2 24 | $7.8B | — | ||
| Q1 24 | $7.7B | — |
总资产COOMRNA
| Q4 25 | $12.4B | — | ||
| Q3 25 | $12.4B | $12.1B | ||
| Q2 25 | $12.4B | — | ||
| Q1 25 | $12.2B | — | ||
| Q4 24 | $12.3B | $14.1B | ||
| Q3 24 | $12.1B | $15.8B | ||
| Q2 24 | $12.0B | — | ||
| Q1 24 | $12.0B | — |
负债/权益比COOMRNA
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.29× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 0.32× | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.34× | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $247.9M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | $149.9M | $-880.0M |
| 自由现金流率自由现金流/营收 | 14.1% | -86.6% |
| 资本支出强度资本支出/营收 | 9.2% | 3.2% |
| 现金转化率经营现金流/净利润 | 2.93× | — |
| 过去12个月自由现金流最近4个季度 | $433.7M | $-1.9B |
8季度趋势，按日历期对齐
经营现金流COOMRNA
| Q4 25 | $247.9M | — | ||
| Q3 25 | $261.4M | $-847.0M | ||
| Q2 25 | $96.2M | — | ||
| Q1 25 | $190.6M | — | ||
| Q4 24 | $268.1M | $825.0M | ||
| Q3 24 | $207.5M | $-1.6B | ||
| Q2 24 | $111.0M | — | ||
| Q1 24 | $122.7M | — |
自由现金流COOMRNA
| Q4 25 | $149.9M | — | ||
| Q3 25 | $164.5M | $-880.0M | ||
| Q2 25 | $18.1M | — | ||
| Q1 25 | $101.2M | — | ||
| Q4 24 | $128.1M | $303.0M | ||
| Q3 24 | $118.5M | $-1.7B | ||
| Q2 24 | $36.9M | — | ||
| Q1 24 | $4.6M | — |
自由现金流率COOMRNA
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.5% | -86.6% | ||
| Q2 25 | 1.8% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 12.6% | 31.4% | ||
| Q3 24 | 11.8% | -92.2% | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 0.5% | — |
资本支出强度COOMRNA
| Q4 25 | 9.2% | — | ||
| Q3 25 | 9.1% | 3.2% | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 13.7% | 54.0% | ||
| Q3 24 | 8.9% | 8.1% | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 12.7% | — |
现金转化率COOMRNA
| Q4 25 | 2.93× | — | ||
| Q3 25 | 2.66× | — | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.83× | — | ||
| Q4 24 | 2.28× | — | ||
| Q3 24 | 1.98× | -120.46× | ||
| Q2 24 | 1.25× | — | ||
| Q1 24 | 1.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
